A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF SUBCUTANEOUSLY ADMINISTERED GUSELKUMAB IN IMPROVING THE SIGNS AND SYMPTOMS AND INHIBITING RADIOGRAPHIC PROGRESSION IN PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS (APEX)
- Registry ID
- CNTO1959PSA3004
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- JANSSEN RESEARCH AND DEVELOPMENT LLC
- Start date
- 2022-01-04
- Last update
- 2021-06-15
Conditions
- ACTIVE PSORIATIC ARTHRITIS
Related clinical trials
- A PHASE 2 MULTICENTER, RANDOMIZED, PLATFORM STUDY OF TARGETED THERAPIES FOR THE TREATMENT OF ADULT SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
- A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED PHASE 3
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASOCITINIB (TAK-279) IN SUBJECTS
WITH ACTIVE PSORIATIC ARTHRITIS STRATIFIED BY PRIOR BIOLOGIC USE (LATITUDE-PSA-
3002)
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF JNJ-77242113 FOR THE TREATMENT OF BIOLOGIC-EXPERIENCED AND BIOLOGIC-NAÏVE PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS
- A PHASE 3, PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, 3-ARM, PLACEBOCONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF
SUBCUTANEOUS SONELOKIMAB IN MALE AND FEMALE PARTICIPANTS AGED 18 YEARS AND
OVER WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE NAIVE TO BIOLOGIC DMARDS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2B/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IZOKIBEP IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
- A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP 690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
View on source registry